亚辉龙牵手两所高校共建联合实验室,加速布局神经诊疗与智能诊断新赛道

Group 1 - The core viewpoint of the news is that Aihua Long has established two joint laboratories with universities in Shenzhen, focusing on neurological diagnosis and intelligent diagnosis, which signifies the company's commitment to advancing its capabilities in the in vitro diagnostics and life health sectors [1][2][3] Group 2 - The "Neurodiagnosis Joint Laboratory" with the Chinese University of Hong Kong (Shenzhen) will focus on major neurodegenerative diseases such as Alzheimer's and Parkinson's, conducting systematic research on disease biomarkers, diagnostic technology, and key equipment development [1] - The "Intelligent Diagnosis and Precision Medicine Joint Laboratory" with Shenzhen Technology University will concentrate on AI image recognition systems, microfluidic detection platforms, and the development of new biological markers, aiming to convert core R&D results into marketable products within 3 to 5 years [2] - Aihua Long's collaboration with these universities reflects a strategy of integrating clinical needs with industrial transformation, emphasizing a systematic and institutional long-term cooperation model [2][3] - The establishment of these laboratories is expected to enhance Aihua Long's product line and technical reserves, contributing to the high-quality development of the biopharmaceutical industry in the Guangdong-Hong Kong-Macao Greater Bay Area [3] - The company aims to create a comprehensive innovation ecosystem in the health industry through the integration of research, technology development, product transformation, and clinical application [2][3]